EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine

Anna Reznichenko, Viji Nair, Sean Eddy, Damian Fermin, Mark Tomilo, Timothy Slidel, Wenjun Ju, Ian Henry, Shawn S Badal, Johnna D Wesley, John T Liles, Sven Moosmang und 12 weitere

Kidney International · 2024-06 · 105 (6) · 1263-1278

DOI: 10.1016/j.kint.2024.01.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Kidney International, 2024-06. Verfasst von Anna Reznichenko und 23 weiteren Autor:innen. Beteiligte Einrichtung: Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZen…. Hauptthemen laut MEDLINE: Precision Medicine, Renal Insufficiency, Chronic, Glomerular Filtration Rate, Disease Progression. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK NIH HHS, NIDDK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current classification of chronic kidney disease (CKD) into stages using indirect systemic measures (estimated glomerular filtration rate (eGFR) and albuminuria) is agnostic to the heterogeneity of underlying molecular processes in the kidney thereby limiting precision medicine approaches. To generate a novel CKD categorization that directly reflects within kidney disease drivers we analyzed publicly available transcriptomic data from kidney biopsy tissue. A Self-Organizing Maps unsupervised artificial neural network machine-learning algorithm was used to stratify a total of 369 patients with CKD and 46 living kidney donors as healthy controls. Unbiased stratification of the discovery cohort resulted in identification of four novel molecular categories of disease termed CKD-Blue, CKD-Gold, CKD-Olive, CKD-Plum that were replicated in independent CKD and diabetic kidney disease datasets and can be further tested on any external data at kidneyclass.org. Each molecular category spanned across CKD stages and histopathological diagnoses and represented transcriptional activation of distinct biological pathways. Disease progression rates were highly significantly different between the molecular categories. CKD-Gold displayed rapid progression, with significant eGFR-adjusted Cox regression hazard ratio of 5.6 [1.01-31.3] for kidney failure and hazard ratio of 4.7 [1.3-16.5] for composite of kidney failure or a 40% or more eGFR decline. Urine proteomics revealed distinct patterns between the molecular categories, and a 25-protein signature was identified to distinguish CKD-Gold from other molecular categories. Thus, patient stratification based on kidney tissue omics offers a gateway to non-invasive biomarker-driven categorization and the potential for future clinical implementation, as a key step towards precision medicine in CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Precision MedicineRenal Insufficiency, ChronicGlomerular Filtration RateDisease ProgressionKidneyTranscriptomeHumansMiddle AgedFemaleMaleAgedBiopsyAdultNeural Networks, ComputerCase-Control StudiesGene Expression ProfilingUnsupervised Machine Learning

Stichwörter der Autor:innen

gene expressionkidney biopsymachine learningpatient stratificationprecision medicinetissue transcriptomics

Autor:innen und Institutionen

  • Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden. Electronic address: anna.reznichenko@astrazen…
  • Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, Michigan, USA.
  • Early Computational Oncology, Translational Medicine, Research and Early Development, Oncology R&D, AstraZeneca, Cambridge, UK.
  • Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Gilead Sciences, Foster City, California, USA.
  • Novo Nordisk Research Center Seattle, Seattle, Washington, USA.

Förderung

  • NIDDK NIH HHS
  • NIDDK

Zitieren

APA

Reznichenko, A., Nair, V., Eddy, S., Fermin, D., Tomilo, M., Slidel, T., Ju, W., Henry, I., Badal, S. S., Wesley, J. D., Liles, J. T., Moosmang, S., Williams, J. M., Quinn, C. M., Bitzer, M., Hodgin, J. B., Barisoni, L., Karihaloo, A., Breyer, M. D., …, & Kretzler, M. (2024). Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine. Kidney International, 105(6), 1263-1278. https://doi.org/10.1016/j.kint.2024.01.012

Vancouver

Reznichenko A, Nair V, Eddy S, Fermin D, Tomilo M, Slidel T, et al. Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine. Kidney International. 2024;105(6):1263-1278. doi:10.1016/j.kint.2024.01.012

BibTeX
@article{Reznichenko2024,
  author = {Reznichenko, Anna and Nair, Viji and Eddy, Sean and Fermin, Damian and Tomilo, Mark and Slidel, Timothy and Ju, Wenjun and Henry, Ian and Badal, Shawn S and Wesley, Johnna D and Liles, John T and Moosmang, Sven and Williams, Julie M and Quinn, Carol Moreno and Bitzer, Markus and Hodgin, Jeffrey B and Barisoni, Laura and Karihaloo, Anil and Breyer, Matthew D and Duffin, Kevin L and Patel, Uptal D and Magnone, Maria Chiara and Bhat, Ratan and Kretzler, Matthias},
  title = {Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine},
  journal = {Kidney International},
  year = {2024},
  volume = {105},
  number = {6},
  pages = {1263--1278},
  doi = {10.1016/j.kint.2024.01.012}
}
Kostenlos starten →